-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, many pharmaceutical companies have announced that they will build production bases
.
Some aim to upgrade the industry and improve production and distribution capabilities; some aim to further expand the company's production capacity and improve market competitiveness
.
Among them, it is worth noting that two more pharmaceutical companies announced on the same day that they will spend huge sums of money to build production projects
.
Nanjing Pharmaceuticals subsidiary plans to invest 472 million yuan in the construction of Fujian Tongchun Biomedicine Industrial Park Project On November 30, Nanjing Pharmaceuticals announced that the company’s holding subsidiary Fujian Tongchun intends to invest in the construction of the first phase of Fujian Tongchun Biomedical Industrial Park.
The total investment of the project is about 471.
6 million yuan
.
Nanjing Pharmaceuticals stated that the construction of the Fujian Tongchun Biomedical Industrial Park (Phase I) will be based on the guiding principles of "standardization of logistics operations, refined logistics services, and marketization of logistics costs" to effectively integrate the existing parent and subsidiary companies of Fujian Tongchun in Fuzhou.
Have office, warehouse and other resources and reconfigure them reasonably, with the goal of "automation of warehousing equipment, informatization of drug management, barcode of logistics process, integration of warehousing and distribution, and professionalization of logistics talents", so as to achieve a logistics center distribution carrying capacity of 8.
7 billion yuan The size of the distribution
.
After the project is completed, it is expected to meet the development needs of Fujian Tongchun in the next 5-8 years, as well as the logistics expansion and reserve capacity of 8-12 years
.
Haixiang Pharmaceutical intends to invest 2 billion yuan to build a comprehensive production base project in Hubei Pharmaceutical and Chemical Industry.
On November 30, Haixiang Pharmaceutical issued an announcement stating that it intends to establish a wholly-owned subsidiary Yichang Haixiang Pharmaceutical Co.
, Ltd.
in Hubei Province.
Jiang City Yaojiagang Chemical Park purchased about 500 acres of land use rights and invested in the construction of Hubei Pharmaceutical and Chemical Comprehensive Production Base Project
.
It is reported that the project is divided into two phases to build production lines of various raw materials, pharmaceutical intermediates and fine chemicals.
The total investment of the project is estimated to be about 2 billion yuan
.
Among them, the land for the first phase of the project is about 300 acres, and the land for the second phase of the project is about 200 acres.
The first phase of the project is planned to start construction in April 2022 with a construction period of 12 months.
It is planned to be officially put into operation in April 2023
.
Haixiang Pharmaceutical is a comprehensive medical enterprise covering the entire industry chain of medicine and dyes
.
Among them, Haixiang Pharmaceutical's pharmaceutical business involves the R&D, commercial production and sales of specialty APIs, pharmaceutical intermediates, and generic drugs, and provides customized R&D and production services (CMO/CDMO) for world-renowned pharmaceutical companies
.
Regarding the investment and construction, Haixiang Pharmaceuticals stated that the company’s planned investment and construction projects focus on the pharmaceutical business to accelerate its industrial layout.
Through the construction of new production bases, it will gradually expand and upgrade production capacity, improve the industrial chain layout, expand the company’s business scale, and consolidate the company.
Dominant position in the field of APIs
.
At the same time, this investment and construction can also help Haixiang Pharmaceutical to accelerate the industrialization of existing reserves of new products and new processes, optimize product structure, enhance the company's comprehensive competitiveness, create new profit growth points for the company, and promote the company's long-term, Healthy and sustainable development
.
Conclusion The analysis believes that in the future, in order to meet the continuous increase in industrial demand, more and more pharmaceutical companies will also choose to build and purchase production bases to expand their company's production capacity and improve market competitiveness
.
In this context, it is expected that pharmaceutical equipment companies that are closely related to drug production and the pharmaceutical industry will also usher in more opportunities
.
.
Some aim to upgrade the industry and improve production and distribution capabilities; some aim to further expand the company's production capacity and improve market competitiveness
.
Among them, it is worth noting that two more pharmaceutical companies announced on the same day that they will spend huge sums of money to build production projects
.
Nanjing Pharmaceuticals subsidiary plans to invest 472 million yuan in the construction of Fujian Tongchun Biomedicine Industrial Park Project On November 30, Nanjing Pharmaceuticals announced that the company’s holding subsidiary Fujian Tongchun intends to invest in the construction of the first phase of Fujian Tongchun Biomedical Industrial Park.
The total investment of the project is about 471.
6 million yuan
.
Nanjing Pharmaceuticals stated that the construction of the Fujian Tongchun Biomedical Industrial Park (Phase I) will be based on the guiding principles of "standardization of logistics operations, refined logistics services, and marketization of logistics costs" to effectively integrate the existing parent and subsidiary companies of Fujian Tongchun in Fuzhou.
Have office, warehouse and other resources and reconfigure them reasonably, with the goal of "automation of warehousing equipment, informatization of drug management, barcode of logistics process, integration of warehousing and distribution, and professionalization of logistics talents", so as to achieve a logistics center distribution carrying capacity of 8.
7 billion yuan The size of the distribution
.
After the project is completed, it is expected to meet the development needs of Fujian Tongchun in the next 5-8 years, as well as the logistics expansion and reserve capacity of 8-12 years
.
Haixiang Pharmaceutical intends to invest 2 billion yuan to build a comprehensive production base project in Hubei Pharmaceutical and Chemical Industry.
On November 30, Haixiang Pharmaceutical issued an announcement stating that it intends to establish a wholly-owned subsidiary Yichang Haixiang Pharmaceutical Co.
, Ltd.
in Hubei Province.
Jiang City Yaojiagang Chemical Park purchased about 500 acres of land use rights and invested in the construction of Hubei Pharmaceutical and Chemical Comprehensive Production Base Project
.
It is reported that the project is divided into two phases to build production lines of various raw materials, pharmaceutical intermediates and fine chemicals.
The total investment of the project is estimated to be about 2 billion yuan
.
Among them, the land for the first phase of the project is about 300 acres, and the land for the second phase of the project is about 200 acres.
The first phase of the project is planned to start construction in April 2022 with a construction period of 12 months.
It is planned to be officially put into operation in April 2023
.
Haixiang Pharmaceutical is a comprehensive medical enterprise covering the entire industry chain of medicine and dyes
.
Among them, Haixiang Pharmaceutical's pharmaceutical business involves the R&D, commercial production and sales of specialty APIs, pharmaceutical intermediates, and generic drugs, and provides customized R&D and production services (CMO/CDMO) for world-renowned pharmaceutical companies
.
Regarding the investment and construction, Haixiang Pharmaceuticals stated that the company’s planned investment and construction projects focus on the pharmaceutical business to accelerate its industrial layout.
Through the construction of new production bases, it will gradually expand and upgrade production capacity, improve the industrial chain layout, expand the company’s business scale, and consolidate the company.
Dominant position in the field of APIs
.
At the same time, this investment and construction can also help Haixiang Pharmaceutical to accelerate the industrialization of existing reserves of new products and new processes, optimize product structure, enhance the company's comprehensive competitiveness, create new profit growth points for the company, and promote the company's long-term, Healthy and sustainable development
.
Conclusion The analysis believes that in the future, in order to meet the continuous increase in industrial demand, more and more pharmaceutical companies will also choose to build and purchase production bases to expand their company's production capacity and improve market competitiveness
.
In this context, it is expected that pharmaceutical equipment companies that are closely related to drug production and the pharmaceutical industry will also usher in more opportunities
.
